Summary of Presentations from the Gilead Sciences (Europe) Symposium, held at the 49th Annual EASL ILC, London, UK, on 9th April 2014
Chairperson: Graham Foster,1 Patrick Marcellin2
Speakers: Ira Jacobson,3 Heiner Wedemeyer,4 Christophe Hézode,5 Antonio Craxì6
1. Queen Mary University of London, London, UK
2. Université Paris-Diderot, Paris, France
3. Weil Cornell Medical College, New York, USA
4. Hannover Medical School, Hannover, Germany
5. Hôpital Henri Mondor, Créteil, France
6. University of Palermo, Palermo, Italy
Disclosure: Speakers participating in this symposium received honorarium from Gilead Sciences, Europe. Any patient cases and treatment options referred to are in the context of contemporary knowledge and medical practice in the field. For scientific completion, the educational symposium included reference to unlicensed products or unlicensed indications; where products in development are discussed, only those at the most advanced stages of development are included.
Acknowledgements: Writing assistance provided by Dr Tabasum Mughal.
Support: The publication of this article was funded by Gilead Sciences, Europe. The views and opinions expressed are those of the authors and which were based on information and data available at the time and not necessarily of Gilead Sciences, Europe.
Citation: EMJ Hepatol. 2014;1:36-41.
This Gilead-sponsored satellite symposium addressed the new and exciting advent of novel therapy in the field of hepatitis C by highlighting recent important clinical trials. The scientific programme covered the history of treatment of hepatitis C and the current and future treatment landscape in the management of hepatitis C virus (HCV) infection.